The impact of recombinant erythropoietin on neuro-developmental outcome in perinatal asphyxia
DOI:
https://doi.org/10.18203/2349-3291.ijcp20251088Keywords:
Erythropoietin, Perinatal asphyxia, Hypoxic-ischemic encephalopathy, Neurological outcomeAbstract
Background: Perinatal asphyxia is a leading cause of neonatal mortality, morbidity, and neurodevelopmental impairments. While therapeutic hypothermia is standard in high-income countries, it has not shown benefits in low- and middle-income settings. Alternative neuroprotective strategies, such as erythropoietin with its regenerative properties, are needed. This study evaluates the efficacy of recombinant erythropoietin in improving short-term neurodevelopmental outcomes in term neonates with moderate to severe hypoxic-ischemic encephalopathy.
Methods: A randomized controlled trial was conducted at Bangladesh Shishu Hospital and Institute over two years, enrolling 88 neonates. Group A received standard treatment plus recombinant human erythropoietin (500 U/kg subcutaneously within 24 hours of birth, followed by daily doses for five days), while group B received standard care alone. Short-term outcomes, including seizure control, oral feeding tolerance, hospital stay, mortality, and neurodevelopment at discharge and three months, were assessed.
Results: Both groups had comparable baseline characteristics. Group A had significantly faster seizure control (27.02±11.18 hours, p<0.001) and a lower need for multiple seizure drugs (20.5%, p=0.002). They also achieved full oral feeding earlier (8.50±1.54 versus 9.40±1.89 days, p=0.022). No significant differences were observed in hospital stay or mortality. Neurological abnormalities at discharge and three months were lower in group A (40.54% versus 70.59%; 23.5% versus 53.33%). Gross motor impairments were also significantly reduced (p=0.003).
Conclusions: Erythropoietin improves short-term neurological outcomes in neonates with perinatal asphyxia, particularly when administered within 24 hours of birth.
Metrics
References
UNICEF. Neonatal mortality data. 2023. Available at: https://data.unicef.org/topic/child-survival/neona tal-mortality. Accessed on 12 January 2025.
Hug L, Alexander M, You D, Alkema L. National, regional, and global levels and trends in neonatal mortality between 1990 and 2017, with scenario-based projections to 2030: a systematic analysis. Lancet Glob Health. 2019;7(6):e710-20. DOI: https://doi.org/10.1016/S2214-109X(19)30163-9
Ivain P, Montaldo P, Khan A, Elagovan R, Burgod C, Morales MM, et al. Erythropoietin monotherapy for neuroprotection after neonatal encephalopathy in low-to-middle income countries: a systematic review and meta-analysis. J Perinatol. 2021;41(9):2134-40. DOI: https://doi.org/10.1038/s41372-021-01132-4
Aktar F, Dutta S, Rahman MZ, Roni MP, Ahmed W. Perinatal Asphyxia and Associated Factors among Neonates Admitted to a Tertiary Hospital in Chattogram, Bangladesh. J Chittagong Med Coll Teachers' Assoc. 2023;34(1):36-40.
Getachew T, Tadesse M, Batu D, Gebre DS, Tololu AK, Bayou H, Simie H. Determinants of Birth Asphyxia among New Born Babies in Bekoji Public Hospital, Arsi Zone, Oromia Regional State, Ethiopia, 2023 Unmatched case control study design. J Neonat Care. 2024;14:2. DOI: https://doi.org/10.15406/jpnc.2024.14.00548
Ahearne CE, Boylan GB, Murray DM. Short and long term prognosis in perinatal asphyxia: An update. World J Clin Pediatr. 2016;5(1):67. DOI: https://doi.org/10.5409/wjcp.v5.i1.67
Perrone S, Lembo C, Gironi F, Petrolini C, Catalucci T, Corbo G, et al. Erythropoietin as a neuroprotective drug for newborn infants: ten years after the first use. Antioxidants. 2022;11(4):652. DOI: https://doi.org/10.3390/antiox11040652
Nair J, Kumar VH. Current and emerging therapies in the management of hypoxic ischemic encephalopathy in neonates. Children. 2018;5(7):99. DOI: https://doi.org/10.3390/children5070099
Agarwal R, Deorari A, Paul VK. AIIMS Protocols in Neonatology. 2nd Edition. Noble Vision. 2019.
Thayyil S, Pant S, Montaldo P, Shukla D, Oliveira V, Ivain P, et al. Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh. Lancet Glob Health. 2021;9(9):e1273-85.
Oorschot DE, Sizemore RJ, Amer AR. Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: history, current status, and future research. Int J Mol Sci. 2020;21(4):1487. DOI: https://doi.org/10.3390/ijms21041487
Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2):e218-26. DOI: https://doi.org/10.1542/peds.2008-3553
Malla RR, Bhat MA. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol. 2018;38(3):294. DOI: https://doi.org/10.1038/s41372-018-0054-6
Mehnaz S, Chowdhury MA, Yasmeen BN, Rahman MM, Akter RJ, Afrin M, et al. Role of Human Recombinant Erythropoietin (rHuEPO) in Perinatal Asphyxia-a randomized controlled trial. Northern Int Med Coll J. 2018;10(1):330-4. DOI: https://doi.org/10.3329/nimcj.v10i1.39326
Elmahdy H, El-Mashad AR, El-Bahrawy H, El-Gohary T, El-Barbary A, Aly H. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics. 2010;125(5):e1135-42. DOI: https://doi.org/10.1542/peds.2009-2268
El Shimi MS, Awad HA, Hassanein SM, Gad GI, Imam SS, Shaaban HA, et al. Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings. J Maternal-Fetal Neonat Med. 2014;27(13):1295-300. DOI: https://doi.org/10.3109/14767058.2013.855894
Basiri B, Shokouhi M, Sabzehei MK, Navid TG, Eghbalian F, Khanlarzadeh E. Effect of Erythropoietin on Short-term Prognosis of Newborns with Hypoxic-Ischemic Encephalopathy: A Clinical Trial. Iranian J Pediatr. 2022;32(4). DOI: https://doi.org/10.5812/ijp-122193
Glass HC, Wusthoff CJ, Comstock BA, Numis AL, Gonzalez FF, Maitre N, et al. Risk of seizures in neonates with hypoxic-ischemic encephalopathy receiving hypothermia plus erythropoietin or placebo. Pediatr Res. 2023;94(1):252-9. DOI: https://doi.org/10.1038/s41390-022-02398-w
Avasiloaiei A, Dimitriu C, Moscalu M, Paduraru L, Stamatin M. High‐dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns. Pediatr Int. 2013;55(5):589-93. DOI: https://doi.org/10.1111/ped.12121
Downloads
Published
How to Cite
Issue
Section
